Kathleen M Hayden1, Oksana A Makeeva2, L Kristin Newby3, Brenda L Plassman4, Valentina V Markova2, Ashley Dunham5, Heather R Romero4, Zarui A Melikyan2, Cassandra M Germain4, Kathleen A Welsh-Bohmer4, Allen D Roses6. 1. Department of Psychiatry, Joseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC, USA. Electronic address: khayden@duke.edu. 2. Center for Clinical Trials, Nebbiolo LLC, Tomsk, Russia. 3. Duke Clinical Research Institute, Durham, NC, USA; Department of Medicine, Duke University Medical Center, Durham, NC, USA. 4. Department of Psychiatry, Joseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC, USA. 5. Duke Clinical Research Institute, Durham, NC, USA. 6. Zinfandel Pharmaceuticals, Durham, NC, USA.
Abstract
BACKGROUND: Understanding regional differences in cognitive performance is important for interpretation of data from large multinational clinical trials. METHODS: Data from Durham and Cabarrus Counties in North Carolina, USA and Tomsk, Russia (n = 2972) were evaluated. The Montreal Cognitive Assessment (MoCA), Trail Making Test Part B (Trails B), Consortium to Establish a Registry for Alzheimer's Disease Word List Memory Test (WLM) delayed recall, and self-report Alzheimer's Disease Cooperative Studies Mail-In Cognitive Function Screening Instrument (MCFSI) were administered at each site. Multilevel modeling measured the variance explained by site and predictors of cognitive performance. RESULTS: Site differences accounted for 11% of the variation in the MoCA, 1.6% in Trails B, 1.7% in WLM, and 0.8% in MCFSI scores. Prior memory testing was significantly associated with WLM. Diabetes and stroke were significantly associated with Trails B and MCFSI. CONCLUSIONS: Sources of variation include cultural differences, health conditions, and exposure to test stimuli. Findings highlight the importance of local norms to interpret test performance.
BACKGROUND: Understanding regional differences in cognitive performance is important for interpretation of data from large multinational clinical trials. METHODS: Data from Durham and Cabarrus Counties in North Carolina, USA and Tomsk, Russia (n = 2972) were evaluated. The Montreal Cognitive Assessment (MoCA), Trail Making Test Part B (Trails B), Consortium to Establish a Registry for Alzheimer's DiseaseWord List Memory Test (WLM) delayed recall, and self-report Alzheimer's Disease Cooperative Studies Mail-In Cognitive Function Screening Instrument (MCFSI) were administered at each site. Multilevel modeling measured the variance explained by site and predictors of cognitive performance. RESULTS: Site differences accounted for 11% of the variation in the MoCA, 1.6% in Trails B, 1.7% in WLM, and 0.8% in MCFSI scores. Prior memory testing was significantly associated with WLM. Diabetes and stroke were significantly associated with Trails B and MCFSI. CONCLUSIONS: Sources of variation include cultural differences, health conditions, and exposure to test stimuli. Findings highlight the importance of local norms to interpret test performance.
Keywords:
Alzheimer's disease; Cross-cultural comparison; Neuropsychological tests; Primary prevention delay of onset of MCI due to Alzheimer's disease
Authors: Joan M McDowd; Diane L Filion; Patricia S Pohl; Lorie G Richards; William Stiers Journal: J Gerontol B Psychol Sci Soc Sci Date: 2003-01 Impact factor: 4.077
Authors: Sayanti Bhattacharya; Ashley A Dunham; Melissa A Cornish; Victoria A Christian; Geoffrey S Ginsburg; Jessica D Tenenbaum; Meredith L Nahm; Marie Lynn Miranda; Robert M Califf; Rowena J Dolor; L Kristin Newby Journal: Am J Transl Res Date: 2012-10-10 Impact factor: 4.060
Authors: J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark Journal: Neurology Date: 1989-09 Impact factor: 9.910
Authors: Frans R Verhey; Peter Houx; Natascha Van Lang; Felicia Huppert; Gabriella Stoppe; Jos Saerens; Peter Böhm; Luc De Vreese; Arto Nordlund; Peter P DeDeyn; Mirco Neri; Jordi Peña-Casanova; Anders Wallin; Eduard Bollen; Huub Middelkoop; Marie-Christine Nargeot; Michèle Puel; Ulrich M Fleischmann; Jellemer Jolles Journal: Int J Geriatr Psychiatry Date: 2004-01 Impact factor: 3.485
Authors: Perminder S Sachdev; Darren M Lipnicki; Nicole A Kochan; John D Crawford; Anbupalam Thalamuthu; Gavin Andrews; Carol Brayne; Fiona E Matthews; Blossom C M Stephan; Richard B Lipton; Mindy J Katz; Karen Ritchie; Isabelle Carrière; Marie-Laure Ancelin; Linda C W Lam; Candy H Y Wong; Ada W T Fung; Antonio Guaita; Roberta Vaccaro; Annalisa Davin; Mary Ganguli; Hiroko Dodge; Tiffany Hughes; Kaarin J Anstey; Nicolas Cherbuin; Peter Butterworth; Tze Pin Ng; Qi Gao; Simone Reppermund; Henry Brodaty; Nicole Schupf; Jennifer Manly; Yaakov Stern; Antonio Lobo; Raúl Lopez-Anton; Javier Santabárbara Journal: PLoS One Date: 2015-11-05 Impact factor: 3.240